Business Valuation Zone

GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca

Benzinga

DECEMBER 30, 2022

GSK plc (NYSE: GSK ) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 ' Luke added that GSK is looking to acquire or partner with biotechs' hiding in plain sight' to expand its pipeline. billion (£1.5.

Equity

This Analyst Says GSK Spin-Off Haleon Offers "Best Of Both Consumer Worlds"

Benzinga

JULY 22, 2022

Citi group has initiated coverage on GSK plc's (NYSE: GSK ) consumer healthcare spin-off Haleon Plc (NYSE: HLN ) with a Buy rating and a price target of 360p.

GSK Confirms Consumer Healthcare Unit Spin-off: What Investors Should Know

Benzinga

JUNE 1, 2022

Close on the heels of an M&A deal , GlaxoSmithKline plc (NYSE: GSK ) confirmed the spin-off of the consumer healthcare business it jointly owns with U.S. What Happened: GSK said it is spinning off its consumer healthcare business into an independently-traded public company, named Haleon, a regulatory filing on Wednesday showed.

Dividends

GSK Completes Spin Off Of Its Consumer Healthcare Business

Benzinga

JULY 18, 2022

GSK plc (NYSE: GSK ) has completed the demerger of the Consumer Healthcare business to form the Haleon Group. The company's debut price was in line with market expectations, according to two bankers involved. billion ($36.4

Marketability

GSK To Strengthen Specialty Medicines and Respiratory Pipeline With $2B BELLUS Health Acquisition

Benzinga

APRIL 18, 2023

GSK Plc (NYSE: GSK ) has agreed to acquire the late-stage biopharmaceutical company BELLUS Health Inc (NASDAQ: BLU ) for $14.75 Following the anticipated regulatory approval and launch of camlipixant in 2026, the company's acquisition is expected to be accretive to. billion (£1.6

Equity

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More

Benzinga

APRIL 13, 2022

Halozyme Buys Specialty Product Company Antares In $960M Deal. GlaxoSmithKline plc (NYSE: GSK ) has agreed to acquire Sierra Oncology Inc (NASDAQ: SRRA ) for $55 per share in cash, equivalent to an equity value of $1.9 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus.

Equity

Equity Technology

GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health

Business Wire M&A

APRIL 18, 2023

LONDON--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. The acquisition provides GSK access to camlipixa per share of common stock in cash representing an approximate total equity value of US$2.0 billion (£1.6 billion). (TSX/NASDAQ: billion (£1.6

Equity

Sierra Oncology Stock Is Soaring: Here's Why

Benzinga

APRIL 13, 2022

Sierra Oncology Inc (NASDAQ: SRRA ) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK ) for $55 per share in cash, representing an approximate total equity value of $1.9

Equity

Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests

Benzinga

JULY 13, 2022

NASDAQ: TBPH ) has agreed to sell all of its units in Theravance Respiratory Company , LLC, representing 85% economic interest in the sales-based royalty rights on worldwide net sales of GSK plc’s (NYSE: GSK ) TRELEGY ELLIPTA to Royalty Pharma (NASDAQ: RPRX ) for over $1.5 Theravance Biopharma, Inc.

4 Firms Guide GSK's $2B Bellus Cough Drug Co. Takeover

Law 360 M&A

APRIL 18, 2023

Pharmaceuticals giant GSK PLC, the former GlaxoSmithKline, said on Tuesday that it has agreed to buy Canadian respiratory treatment company Bellus Health Inc. in an all-cash deal valued at $2 billion.

BELLUS Health Announces Meeting Updates

Business Wire M&A

APRIL 26, 2023

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc.

Coherus to Acquire Surface Oncology

Benzinga

JUNE 16, 2023

The transaction was unanimously approved by the boards of directors of both companies and is expected to close in the third quarter of 2023. and CAMBRIDGE, Mass., and CAMBRIDGE, Mass., June 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. Coherus, NASDAQ: CHRS ) and Surface Oncology, Inc.

Marketability

Coherus to Acquire Surface Oncology

Benzinga

JUNE 16, 2023

The transaction was unanimously approved by the boards of directors of both companies and is expected to close in the third quarter of 2023. and CAMBRIDGE, Mass., and CAMBRIDGE, Mass., June 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. Coherus, NASDAQ: CHRS ) and Surface Oncology, Inc.

Marketability

Verona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs, Analysts Predict Big Moves

Benzinga

DECEMBER 29, 2023

In recent statements to the Financial Times and The Sunday Times, GSK plc (NYSE: GSK ) Chief Commercial Officer Luke Miels revealed the company's intent to pursue acquisitions within the $2 billion (£1.6 billion) range over the upcoming six months, aiming to fortify its pipeline.

Market Capitalization

Market Capitalization Marketability Equity

Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million

Benzinga

JULY 13, 2022

NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ: RPRX ) today announced that it has agreed to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from Theravance Biopharma, Inc. to 10% on annual worldwide Trelegy sales, payable by GSK. NASDAQ: TBPH ) and Innoviva, Inc. NASDAQ: INVA ) for $1.31

Equity

Equity Marketability

Business Valuation Zone

GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca

This Analyst Says GSK Spin-Off Haleon Offers "Best Of Both Consumer Worlds"

Trending Sources

GSK Confirms Consumer Healthcare Unit Spin-off: What Investors Should Know

GSK Completes Spin Off Of Its Consumer Healthcare Business

GSK To Strengthen Specialty Medicines and Respiratory Pipeline With $2B BELLUS Health Acquisition

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More

GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health

Sierra Oncology Stock Is Soaring: Here's Why

Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests

4 Firms Guide GSK's $2B Bellus Cough Drug Co. Takeover

BELLUS Health Announces Meeting Updates

Coherus to Acquire Surface Oncology

Coherus to Acquire Surface Oncology

Verona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs, Analysts Predict Big Moves

Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million

Stay Connected